{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:03:46Z","timestamp":1793315026375,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T00:00:00Z","timestamp":1562025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T00:00:00Z","timestamp":1562025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA160762"],"award-info":[{"award-number":["R01CA160762"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS032677"],"award-info":[{"award-number":["R01NS032677"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>PARP inhibitors (PARPis) have clinical efficacy in BRCA-deficient cancers, but not BRCA-intact tumors, including glioblastoma (GBM). We show that <jats:italic>MYC<\/jats:italic> or <jats:italic>MYCN<\/jats:italic> amplification in patient-derived glioblastoma stem-like cells (GSCs) generates sensitivity to PARPi via Myc-mediated transcriptional repression of <jats:italic>CDK18<\/jats:italic>, while most tumors without amplification are not sensitive. In response to PARPi, CDK18 facilitates ATR activation by interacting with ATR and regulating ATR-Rad9\/ATR-ETAA1 interactions; thereby promoting homologous recombination (HR) and PARPi resistance. CDK18 knockdown or ATR inhibition in GSCs suppressed HR and conferred PARPi sensitivity, with ATR inhibitors synergizing with PARPis or sensitizing GSCs. ATR inhibitor VE822 combined with PARPi extended survival of mice bearing GSC-derived orthotopic tumors, irrespective of PARPi-sensitivity. These studies identify a role of CDK18 in ATR-regulated HR. We propose that combined blockade of ATR and PARP is an effective strategy for GBM, even for low-Myc GSCs that do not respond to PARPi alone, and potentially other PARPi-refractory tumors.<\/jats:p>","DOI":"10.1038\/s41467-019-10993-5","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T10:02:56Z","timestamp":1562061776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Jian-Fang","family":"Ning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Stanciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa R.","family":"Humphrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Gorham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0225-6424","authenticated-orcid":false,"given":"Hiroko","family":"Wakimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Nishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Lees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Martuza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8225-241X","authenticated-orcid":false,"given":"Hiroaki","family":"Wakimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2795","authenticated-orcid":false,"given":"Samuel D.","family":"Rabkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,2]]},"reference":[{"key":"10993_CR1","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri, A. & Nussenzweig, A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat. Rev. Mol. Cell Biol. 18, 610\u2013621 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10993_CR2","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord, C. J. & Ashworth, A. PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152\u20131158 (2017).","journal-title":"Science"},{"key":"10993_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40265-016-0688-7","volume":"77","author":"G O\u2019Sullivan Coyne","year":"2017","unstructured":"O\u2019Sullivan Coyne, G., Chen, A. P., Meehan, R. & Doroshow, J. H. PARP inhibitors in reproductive system cancers: current use and developments. Drugs 77, 113\u2013130 (2017).","journal-title":"Drugs"},{"key":"10993_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2016.10.010","volume":"108","author":"A Drean","year":"2016","unstructured":"Drean, A., Lord, C. J. & Ashworth, A. PARP inhibitor combination therapy. Crit. Rev. Oncol. Hematol. 108, 73\u201385 (2016).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10993_CR5","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1200\/JCO.2017.73.0119","volume":"35","author":"BM Alexander","year":"2017","unstructured":"Alexander, B. M. & Cloughesy, T. F. Adult glioblastoma. J. Clin. Oncol. 35, 2402\u20132409 (2017).","journal-title":"J. Clin. Oncol."},{"key":"10993_CR6","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1073\/pnas.1219747110","volume":"110","author":"A Sottoriva","year":"2013","unstructured":"Sottoriva, A. et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl Acad. Sci. USA 110, 4009\u20134014 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10993_CR7","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396\u20131401 (2014).","journal-title":"Science"},{"key":"10993_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-1-4939-8805-1_2","volume":"1869","author":"C Chesnelong","year":"2019","unstructured":"Chesnelong, C., Restall, I. & Weiss, S. Isolation and culture of glioblastoma brain tumor stem cells. Methods Mol. Biol. 1869, 11\u201321 (2019).","journal-title":"Methods Mol. Biol."},{"key":"10993_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccr.2006.03.030","volume":"9","author":"J Lee","year":"2006","unstructured":"Lee, J. et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391\u2013403 (2006).","journal-title":"Cancer Cell"},{"key":"10993_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/neuonc\/nor195","volume":"14","author":"H Wakimoto","year":"2012","unstructured":"Wakimoto, H. et al. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol. 14, 132\u2013144 (2012).","journal-title":"Neuro Oncol."},{"key":"10993_CR11","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1101\/gad.261982.115","volume":"29","author":"JD Lathia","year":"2015","unstructured":"Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L. & Rich, J. N. Cancer stem cells in glioblastoma. Genes Dev. 29, 1203\u20131217 (2015).","journal-title":"Genes Dev."},{"key":"10993_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.canlet.2012.05.033","volume":"338","author":"BE Stopschinski","year":"2013","unstructured":"Stopschinski, B. E., Beier, C. P. & Beier, D. Glioblastoma cancer stem cells\u2013from concept to clinical application. Cancer Lett. 338, 32\u201340 (2013).","journal-title":"Cancer Lett."},{"key":"10993_CR13","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1158\/0008-5472.CAN-08-3886","volume":"69","author":"H Wakimoto","year":"2009","unstructured":"Wakimoto, H. et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 69, 3472\u20133481 (2009).","journal-title":"Cancer Res."},{"key":"10993_CR14","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.cell.2014.02.030","volume":"157","author":"ML Suva","year":"2014","unstructured":"Suva, M. L. et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 157, 580\u2013594 (2014).","journal-title":"Cell"},{"key":"10993_CR15","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.4081\/ejh.2012.e9","volume":"56","author":"A Galia","year":"2012","unstructured":"Galia, A. et al. PARP-1 protein expression in glioblastoma multiforme. Eur. J. Histochem. 56, e9 (2012).","journal-title":"Eur. J. Histochem."},{"key":"10993_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/cdd.2013.136","volume":"21","author":"M Venere","year":"2014","unstructured":"Venere, M. et al. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ. 21, 258\u2013269 (2014).","journal-title":"Cell Death Differ."},{"key":"10993_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0427-y","volume":"13","author":"RK Balvers","year":"2015","unstructured":"Balvers, R. K. et al. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells. J. Transl. Med. 13, 74 (2015).","journal-title":"J. Transl. Med."},{"key":"10993_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djw229","volume":"109","author":"J Ning","year":"2017","unstructured":"Ning, J., Wakimoto, H., Peters, C., Martuza, R. L. & Rabkin, S. D. Rad51 degradation: role in oncolytic virus-poly(ADP-ribose) polymerase inhibitor combination therapy in glioblastoma. J. Natl Cancer Inst. 109, 1\u201313 (2017).","journal-title":"J. Natl Cancer Inst."},{"key":"10993_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord, C. J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer 16, 110\u2013120 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"10993_CR20","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12325-015-0214-4","volume":"32","author":"C Rolfo","year":"2015","unstructured":"Rolfo, C. et al. Effect of food on the pharmacokinetics of olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors. Adv. Ther. 32, 510\u2013522 (2015).","journal-title":"Adv. Ther."},{"key":"10993_CR21","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1158\/1078-0432.CCR-13-3052","volume":"20","author":"H Wakimoto","year":"2014","unstructured":"Wakimoto, H. et al. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin. Cancer Res. 20, 2898\u20132909 (2014).","journal-title":"Clin. Cancer Res."},{"key":"10993_CR22","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1158\/1078-0432.CCR-15-2274","volume":"22","author":"K Tateishi","year":"2016","unstructured":"Tateishi, K. et al. Myc-driven glycolysis is a therapeutic target in glioblastoma. Clin. Cancer Res. 22, 4452\u20134465 (2016).","journal-title":"Clin. Cancer Res."},{"key":"10993_CR23","doi-asserted-by":"publisher","first-page":"e00246","DOI":"10.1128\/JVI.00246-18","volume":"92","author":"C Peters","year":"2018","unstructured":"Peters, C. et al. Restriction of replication of oncolytic herpes simplex virus with a deletion of gamma34.5 in glioblastoma stem-like cells. J. Virol. 92, e00246\u201300218 (2018).","journal-title":"J. Virol."},{"key":"10993_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"CV Dang","year":"2012","unstructured":"Dang, C. V. MYC on the path to cancer. Cell 149, 22\u201335 (2012).","journal-title":"Cell"},{"key":"10993_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nature13473","volume":"511","author":"S Walz","year":"2014","unstructured":"Walz, S. et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature 511, 483\u2013487 (2014).","journal-title":"Nature"},{"key":"10993_CR26","doi-asserted-by":"publisher","first-page":"920161","DOI":"10.4061\/2010\/920161","volume":"2010","author":"M Podhorecka","year":"2010","unstructured":"Podhorecka, M., Skladanowski, A. & Bozko, P. H2AX phosphorylation: its role in DNA damage response and cancer therapy. J. Nucleic Acids 2010, 920161 (2010).","journal-title":"J. Nucleic Acids"},{"key":"10993_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/ncb1337","volume":"8","author":"A Jazayeri","year":"2006","unstructured":"Jazayeri, A. et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 8, 37\u201345 (2006).","journal-title":"Nat. Cell Biol."},{"key":"10993_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1146\/annurev-genet-121415-121658","volume":"50","author":"SA Yazinski","year":"2016","unstructured":"Yazinski, S. A. & Zou, L. Functions, regulation, and therapeutic implications of the ATR checkpoint pathway. Annu. Rev. Genet. 50, 155\u2013173 (2016).","journal-title":"Annu. Rev. Genet."},{"key":"10993_CR29","doi-asserted-by":"publisher","first-page":"R33","DOI":"10.1016\/j.cub.2016.11.025","volume":"27","author":"L Zou","year":"2017","unstructured":"Zou, L. DNA replication checkpoint: new ATR activator identified. Curr. Biol. 27, R33\u2013r35 (2017).","journal-title":"Curr. Biol."},{"key":"10993_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/cancers9050041","volume":"9","author":"S Rundle","year":"2017","unstructured":"Rundle, S., Bradbury, A., Drew, Y. & Curtin, N. J. Targeting the ATR-CHK1 axis in cancer therapy. Cancers (Basel) 9, 41 (2017).","journal-title":"Cancers (Basel)"},{"key":"10993_CR31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nm.4032","volume":"22","author":"Y Du","year":"2016","unstructured":"Du, Y. et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat. Med. 22, 194\u2013201 (2016).","journal-title":"Nat. Med."},{"key":"10993_CR32","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.ccell.2016.09.002","volume":"30","author":"NE Muvarak","year":"2016","unstructured":"Muvarak, N. E. et al. Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents - a potential therapy for cancer. Cancer Cell 30, 637\u2013650 (2016).","journal-title":"Cancer Cell"},{"key":"10993_CR33","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/nm.3993","volume":"21","author":"MT Esposito","year":"2015","unstructured":"Esposito, M. T. et al. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors. Nat. Med. 21, 1481\u20131490 (2015).","journal-title":"Nat. Med."},{"key":"10993_CR34","doi-asserted-by":"publisher","first-page":"eaal2463","DOI":"10.1126\/scitranslmed.aal2463","volume":"9","author":"PL Sulkowski","year":"2017","unstructured":"Sulkowski, P. L. et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci. Transl. Med. 9, eaal2463 (2017).","journal-title":"Sci. Transl. Med."},{"key":"10993_CR35","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"10993_CR36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"10993_CR37","doi-asserted-by":"publisher","first-page":"e3769","DOI":"10.1371\/journal.pone.0003769","volume":"3","author":"J Wang","year":"2008","unstructured":"Wang, J. et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS ONE 3, e3769 (2008).","journal-title":"PLoS ONE"},{"key":"10993_CR38","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/0008-5472.CAN-17-1494","volume":"78","author":"JPW Carey","year":"2018","unstructured":"Carey, J. P. W. et al. Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple-negative breast cancer. Cancer Res. 78, 742\u2013757 (2018).","journal-title":"Cancer Res."},{"key":"10993_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","volume":"16","author":"PG Pilie","year":"2019","unstructured":"Pilie, P. G., Tang, C., Mills, G. B. & Yap, T. A. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat. Rev. Clin. Oncol. 16, 81\u2013104 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10993_CR40","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1016\/j.celrep.2018.10.096","volume":"25","author":"E Papp","year":"2018","unstructured":"Papp, E. et al. Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines. Cell Rep. 25, 2617\u20132633 (2018).","journal-title":"Cell Rep."},{"key":"10993_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-54","volume":"13","author":"R Aesoy","year":"2014","unstructured":"Aesoy, R. et al. Regulation of CDKN2B expression by interaction of Arnt with Miz-1\u2013a basis for functional integration between the HIF and Myc gene regulatory pathways. Mol. Cancer 13, 54 (2014).","journal-title":"Mol. Cancer"},{"key":"10993_CR42","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nature01119","volume":"419","author":"J Seoane","year":"2002","unstructured":"Seoane, J., Le, H. V. & Massague, J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729\u2013734 (2002).","journal-title":"Nature"},{"key":"10993_CR43","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/jcb.21765","volume":"104","author":"V Chandramohan","year":"2008","unstructured":"Chandramohan, V. et al. c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor. J. Cell. Biochem. 104, 2091\u20132106 (2008).","journal-title":"J. Cell. Biochem."},{"key":"10993_CR44","doi-asserted-by":"publisher","first-page":"7067","DOI":"10.1158\/1078-0432.CCR-11-1198","volume":"17","author":"A Hoglund","year":"2011","unstructured":"Hoglund, A. et al. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin. Cancer Res. 17, 7067\u20137079 (2011).","journal-title":"Clin. Cancer Res."},{"key":"10993_CR45","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1038\/onc.2017.40","volume":"36","author":"V Colicchia","year":"2017","unstructured":"Colicchia, V. et al. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma. Oncogene 36, 4682\u20134691 (2017).","journal-title":"Oncogene"},{"key":"10993_CR46","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/1078-0432.CCR-17-1872","volume":"24","author":"W Zhang","year":"2018","unstructured":"Zhang, W. et al. Targeting the MYCN-PARP-DNA damage response pathway in neuroendocrine prostate cancer. Clin. Cancer Res. 24, 696\u2013707 (2018).","journal-title":"Clin. Cancer Res."},{"key":"10993_CR47","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.1016\/j.jmb.2013.04.013","volume":"425","author":"C Trovesi","year":"2013","unstructured":"Trovesi, C., Manfrini, N., Falcettoni, M. & Longhese, M. P. Regulation of the DNA damage response by cyclin-dependent kinases. J. Mol. Biol. 425, 4756\u20134766 (2013).","journal-title":"J. Mol. Biol."},{"key":"10993_CR48","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm.2377","volume":"17","author":"N Johnson","year":"2011","unstructured":"Johnson, N. et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat. Med. 17, 875\u2013882 (2011).","journal-title":"Nat. Med."},{"key":"10993_CR49","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","volume":"74","author":"I Bajrami","year":"2014","unstructured":"Bajrami, I. et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity. Cancer Res. 74, 287\u2013297 (2014).","journal-title":"Cancer Res."},{"key":"10993_CR50","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000231895","volume":"17","author":"AR Cole","year":"2009","unstructured":"Cole, A. R. PCTK proteins: the forgotten brain kinases? Neurosignals 17, 288\u2013297 (2009).","journal-title":"Neurosignals"},{"key":"10993_CR51","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.molcel.2016.12.007","volume":"65","author":"R Buisson","year":"2017","unstructured":"Buisson, R. et al. Coupling of homologous recombination and the checkpoint by ATR. Mol. Cell 65, 336\u2013346 (2017).","journal-title":"Mol. Cell"},{"key":"10993_CR52","doi-asserted-by":"publisher","first-page":"8772","DOI":"10.1093\/nar\/gkw615","volume":"44","author":"G Barone","year":"2016","unstructured":"Barone, G. et al. Human CDK18 promotes replication stress signaling and genome stability. Nucleic Acids Res. 44, 8772\u20138785 (2016).","journal-title":"Nucleic Acids Res."},{"key":"10993_CR53","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/nsmb.2189","volume":"18","author":"M Murga","year":"2011","unstructured":"Murga, M. et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat. Struct. Mol. Biol. 18, 1331\u20131335 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10993_CR54","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1172\/JCI58928","volume":"122","author":"DW Schoppy","year":"2012","unstructured":"Schoppy, D. W. et al. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J. Clin. Invest. 122, 241\u2013252 (2012).","journal-title":"J. Clin. Invest."},{"key":"10993_CR55","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","volume":"23","author":"H Kim","year":"2017","unstructured":"Kim, H. et al. Targeting the ATR\/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models. Clin. Cancer Res. 23, 3097\u20133108 (2017).","journal-title":"Clin. Cancer Res."},{"key":"10993_CR56","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","volume":"73","author":"CJ Huntoon","year":"2013","unstructured":"Huntoon, C. J. et al. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res. 73, 3683\u20133691 (2013).","journal-title":"Cancer Res."},{"key":"10993_CR57","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1101\/gad.290957.116","volume":"31","author":"SA Yazinski","year":"2017","unstructured":"Yazinski, S. A. et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 31, 318\u2013332 (2017).","journal-title":"Genes Dev."},{"key":"10993_CR58","doi-asserted-by":"publisher","first-page":"7014","DOI":"10.1158\/0008-5472.CAN-17-2056","volume":"77","author":"SE Jones","year":"2017","unstructured":"Jones, S. E. et al. ATR is a therapeutic target in synovial sarcoma. Cancer Res. 77, 7014\u20137026 (2017).","journal-title":"Cancer Res."},{"key":"10993_CR59","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1158\/0008-5472.CAN-18-0569","volume":"78","author":"RD Carruthers","year":"2018","unstructured":"Carruthers, R. D. et al. Replication stress drives constitutive activation of the DNA damage response and radioresistance in glioblastoma stem-like cells. Cancer Res. 78, 5060\u20135071 (2018).","journal-title":"Cancer Res."},{"key":"10993_CR60","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/gcc.10300","volume":"39","author":"A Pandita","year":"2004","unstructured":"Pandita, A., Aldape, K. D., Zadeh, G., Guha, A. & James, C. D. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 39, 29\u201336 (2004).","journal-title":"Genes Chromosomes Cancer"},{"key":"10993_CR61","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.stem.2018.03.011","volume":"22","author":"X Wang","year":"2018","unstructured":"Wang, X. et al. Reciprocal signaling between glioblastoma stem cells and differentiated tumor cells promotes malignant progression. Cell Stem Cell 22, 514\u2013528.e515 (2018).","journal-title":"Cell Stem Cell"},{"key":"10993_CR62","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.celrep.2013.04.021","volume":"3","author":"E Rheinbay","year":"2013","unstructured":"Rheinbay, E. et al. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 3, 1567\u20131579 (2013).","journal-title":"Cell Rep."},{"key":"10993_CR63","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1002\/ijc.30929","volume":"141","author":"S Esaki","year":"2017","unstructured":"Esaki, S. et al. Blockade of transforming growth factor-beta signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. Int. J. Cancer 141, 2348\u20132358 (2017).","journal-title":"Int. J. Cancer"},{"key":"10993_CR64","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharm. Rev. 58, 621\u2013681 (2006).","journal-title":"Pharm. Rev."},{"key":"10993_CR65","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"10993_CR66","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1172\/JCI70108","volume":"124","author":"DC Christodoulou","year":"2014","unstructured":"Christodoulou, D. C. et al. 5\u2019RNA-Seq identifies Fhl1 as a genetic modifier in cardiomyopathy. J. Clin. Invest. 124, 1364\u20131370 (2014).","journal-title":"J. Clin. Invest."},{"key":"10993_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkn923","volume":"37","author":"W Huang da","year":"2009","unstructured":"Huang da, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1\u201313 (2009).","journal-title":"Nucleic Acids Res."},{"key":"10993_CR68","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"W Huang da","year":"2009","unstructured":"Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44\u201357 (2009).","journal-title":"Nat. Protoc."},{"key":"10993_CR69","doi-asserted-by":"publisher","first-page":"e13984","DOI":"10.1371\/journal.pone.0013984","volume":"5","author":"D Merico","year":"2010","unstructured":"Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G. D. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS ONE 5, e13984 (2010).","journal-title":"PLoS ONE"},{"key":"10993_CR70","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10993-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10993-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10993-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:13:59Z","timestamp":1671236039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10993-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,2]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["10993"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-10993-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,2]]},"assertion":[{"value":"22 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2910"}}